Last reviewed · How we verify

Synbiotic 2000 — Competitive Intelligence Brief

Synbiotic 2000 (Synbiotic 2000) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synbiotic (prebiotic + probiotic combination). Area: Gastroenterology / Immunology.

marketed Synbiotic (prebiotic + probiotic combination) Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Synbiotic 2000 (Synbiotic 2000) — Beth Israel Medical Center. Synbiotic 2000 is a prebiotic and probiotic combination that modulates the gut microbiota to support immune function and gastrointestinal health.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Synbiotic 2000 TARGET Synbiotic 2000 Beth Israel Medical Center marketed Synbiotic (prebiotic + probiotic combination)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synbiotic (prebiotic + probiotic combination) class)

  1. Beth Israel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Synbiotic 2000 — Competitive Intelligence Brief. https://druglandscape.com/ci/synbiotic-2000. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: